More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.04B
EPS
1.73
P/E ratio
13
Price to sales
37.36
Dividend yield
--
Beta
2.968753
Previous close
$16.68
Today's open
$14.34
Day's range
$12.70 - $14.65
52 week range
$6.70 - $21.24
show more
CEO
Gregory A. Demopulos
Employees
175
Headquarters
Seattle, WA
Exchange
NASDAQ Global Market
Shares outstanding
74463571
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Omeros: Yartemlea Commercial Momentum Supports Upgrade Despite Q3 Deceleration (Rating Upgrade)
Omeros earns a speculative buy upgrade: YARTEMLEA's stronger-than-expected launch supports a valuation floor, while zaltenibart and the pipeline offer upside. Q3 net product revenue rose 26% sequentially to $35.9 million, but growth decelerated sharply, and elevated expectations leave little room for disappointment. My revised U.S. model values YARTEMLEA at $870.6 million, with up to $350 million in peak annual sales; OMER's enterprise value is near $1 billion.
Seeking Alpha • 21 hours ago

Omeros Q3 Earnings Call Highlights
Omeros NASDAQ: OMER reported higher third-quarter sales of its transplant complication treatment YARTEMLEA and a second consecutive quarter of positive operating cash flow, while a non-cash adjustment tied to its convertible notes pushed the company to a net loss.
MarketBeat • Nov 17, 2026

Omeros Corporation (OMER) Q3 2026 Earnings Call Transcript
Omeros Corporation (OMER) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 17, 2026

Omeros Corporation Reports Third Quarter 2026 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which include: Third Quarter and Recent Highlights YARTEMLEA® (narsoplimab-wuug), the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”), an often-lethal complication of stem cell transplantation, generated gross revenue of $41.8 million in the third qua.
Business Wire • Nov 16, 2026

Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates
Omeros (OMER) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to a loss of $0.19 per share a year ago.
Zacks Investment Research • Nov 16, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PRNewsWire • Nov 12, 2026

Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the third quarter of 2026 on Monday, November 16, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please c.
Business Wire • Nov 10, 2026

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
Omeros Corporation (NASDAQ:OMER) shares are trading lower Friday after the company announced that the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion from June.
Benzinga • Oct 16, 2026

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (.
Business Wire • Oct 16, 2026

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst
Cantor Fitzgerald on Tuesday upgraded Omeros Corp (NASDAQ:OMER), citing a better-than-expected Yartemlea launch.
Benzinga • Sep 22, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Omeros Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.